A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans

British Journal of Pharmacology

Volumn 171, Issue 11, 2014, Pages 2778-2789

  Hu, Zhe Yi ^a   Lu, Jingtao ^b   Zhao, Yuansheng ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

alvespimycin; drug disposition; Hsp90 inhibitor; interspecies scaling; PBPK modelling

Indexed keywords

ALVESPIMYCIN; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM;

ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; BLOOD; BRAIN; DOSE RESPONSE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG MECHANISM; DRUG URINE LEVEL; HEART; HUMAN; HUMAN TISSUE; KIDNEY; LIVER; LUNG; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES COMPARISON; SPLEEN; TISSUE DISTRIBUTION; VEIN BLOOD FLOW; ANIMAL; BIOLOGICAL MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; HUMANS; LACTAMS, MACROCYCLIC; MICE; MODELS, BIOLOGICAL; RATS; TISSUE DISTRIBUTION;

EID: 84900552156     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12609     Document Type: Article

References (48)

1. Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, et al. (2004). Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos 32: 632-638.
2. Banerji U, (2009). Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15: 9-14.
3. Barrett JS, Della Casa Alberighi O, Laer S, Meibohm B, (2012). Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 92: 40-49.
4. Beliakoff J, Whitesell L, (2004). Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 15: 651-662.
5. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA, (1971). Methotrexate pharmacokinetics. J Pharm Sci 60: 1128-1133.
6. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL, (2007). A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 13: 2768-2776.
7. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP, (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13: 407-484.
8. Charlotte H, (2013). Lead identification: better HSP90 inhibitors. Nat Rev Drug Discov 12: 346.
9. Davies B, Morris T, (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095.
10. Duvvuri M, Konkar S, Hong KH, Blagg BS, Krise JP, (2006). A new approach for enhancing differential selectivity of drugs to cancer cells. ACS Chem Biol 1: 309-315.
11. Edginton AN, Theil FP, Schmitt W, Willmann S, (2008). Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4: 1143-1152.
12. Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, et al. (2002). Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49: 7-19.
13. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, et al. (2005). Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[ [ (2-dimethylamino)ethyl]amino] geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 55: 21-32.
14. Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD, McCormick DL, et al. (2005). Preclinical toxicity of a geldanamycin analog, 17- (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 56: 637-647.
15. Godin SJ, DeVito MJ, Hughes MF, Ross DG, Scollon EJ, Starr JM, et al. (2010). Physiologically based pharmacokinetic modeling of deltamethrin: development of a rat and human diffusion-limited model. Toxicol Sci 115: 330-343.
16. Guo W, Reigan P, Siegel D, Ross D, (2008). Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab Dispos 36: 2050-2057.
17. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R, (2013). Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 39: 375-387.
18. Hu TM, Hayton WL, (2001). Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3: E29.
19. Hudachek SF, Gustafson DL, (2013). Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. J Pharmacokinet Pharmacodyn 40: 157-176.
20. Hwang K, Scripture CD, Gutierrez M, Kummar S, Figg WD, Sparreboom A, (2006). Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 830: 35-40.
21. Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, et al. (2012). A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res 18: 5090-5098.
22. Kagan L, Gershkovich P, Wasan KM, Mager DE, (2011). Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone(R) ): pooled analysis of published data. AAPS J 13: 255-264.
23. Kalvass JC, Maurer TS, Pollack GM, (2007). Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35: 660-666.
24. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. (2003). A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
25. Kenyon EM, (2012). Interspecies extrapolation. Methods Mol Biol 929: 501-520.
26. Khalil F, Laer S, (2011). Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol 2011: 907461.
27. Kim T, Keum G, Pae AN, (2013). Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives. Expert Opin Ther Pat 23: 919-943.
28. Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, et al. (2010). Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46: 340-347.
29. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, et al. (2010). Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24: 699-705.
30. McQueen CA, (2010) Comprehensive Toxicology. Elsevier: Amsterdam.
31. Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, et al. (2006). Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 34: 1480-1487.
32. Ndolo RA, Forrest ML, Krise JP, (2010). The role of lysosomes in limiting drug toxicity in mice. J Pharmacol Exp Ther 333: 120-128.
33. Nestorov I, (2007). Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3: 235-249.
34. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. (2011). A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17: 1561-1570.
35. Pertinez H, Chenel M, Aarons L, (2013). A physiologically based pharmacokinetic model for strontium exposure in rat. Pharm Res 30: 1536-1552.
36. Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, et al. (2010). Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 28: 1520-1526.
37. Rostami-Hodjegan A, (2012). Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 92: 50-61.
38. Rowland M, Tozer TN, (2005) Clinical Pharmacokinetics/Pharmacodynamics. Lippincott Williams and Wilkins: Philadelphia.
39. Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P, (2010). The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS ONE 5: e8933.
40. Scaltriti M, Dawood S, Cortes J, (2012). Molecular pathways: targeting hsp90-who benefits and who does not. Clin Cancer Res 18: 4508-4513.
41. Sharma V, McNeill JH, (2009). To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157: 907-921.
42. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P, (2005). Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 146: 769-780.
43. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010). Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
44. van de Waterbeemd H, Gifford E, (2003). ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2: 192-204.
45. Whitesell L, Lindquist SL, (2005). HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772.
46. Workman P, Powers MV, (2007). Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer. Nat Chem Biol 3: 455-457.
47. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. (2011). Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89: 259-267.
48. Zheng N, Zou P, Wang S, Sun D, (2011). In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes. Drug Metab Dispos 39: 627-635.